Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent

Kirihara T., Taniguchi T., Yamamura K., Iwamura R., Yoneda K., Odani-Kawabata N., Shimazaki A., Matsugi T., Shams N., Zhang J.-Z.

2018
Investigative Ophthalmology and Visual Science

View publication

Therapeutic Area

Glaucoma
Technology

Pharmacology

Affiliations

R & D Division, Santen Pharmaceutical Co., Ltd, Grand Front Osaka Tower A, Kita-Ku, Osaka, Japan; R & D Division, Santen Pharmaceutical Co., Ltd, Ikoma-shi, Nara, Japan; Corporate Research & Development, Ube Industries, Ltd, Ube, Yamaguchi, Japan; R & D Division, Santen Inc, Emeryville, CA, United States

Related Publications

Felodipine re-positioned as a neuroprotectant via improved optic nerve head blood circulation in retinal ischemic rabbits and ocular hypertensive rats

Taniguchi T, Akaishi T, Hata T, Yamashita R, Esaki Y, Morofuji R, Okabe K, Fuwa M, Yamamoto Y, Guo L, Choi S, Luong V, Ota T, Sharif NA, Cordeiro MF, Kageyama M.

A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Konstas A.G.; Garhöfer G.; Lübke Y.; Voykov B.; Ropo A.

Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery

Lo P.F.; Gunawan M.; Yap Z.L.; Leong C.; Kwek F.; Varadarajan J.; Wang X.; Kageyama M.; Wong T.T.

View all Glaucoma publications